Arrowhead Pharmaceuticals - ARWR Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARWR shares.
View ARWR analyst ratings or view top-rated stocks.

6 equities research analysts have issued 12-month target prices for Arrowhead Pharmaceuticals' stock. Their ARWR share price forecasts range from $36.00 to $110.00. On average, they predict the company's share price to reach $66.57 in the next twelve months. This suggests a possible upside of 115.2% from the stock's current price.
View analysts price targets for ARWR or view top-rated stocks among Wall Street analysts.

Arrowhead Pharmaceuticals' stock was trading at $66.30 at the beginning of the year. Since then, ARWR stock has decreased by 53.3% and is now trading at $30.93.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 28th 2022.
View our ARWR earnings forecast.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) posted its quarterly earnings data on Thursday, August, 4th. The biotechnology company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.51) by $0.17. The biotechnology company earned $32.41 million during the quarter, compared to analysts' expectations of $52.61 million. Arrowhead Pharmaceuticals had a negative net margin of 61.58% and a negative trailing twelve-month return on equity of 36.05%. The company's quarterly revenue was down 29.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.29) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), Salesforce (CRM) and Advanced Micro Devices (AMD).

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Arrowhead Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include State Street Corp (5.27%), JPMorgan Chase & Co. (2.83%), FMR LLC (2.59%), Northern Trust Corp (1.22%), Credit Suisse AG (1.21%) and Fiera Capital Corp (1.06%). Insiders that own company stock include Adeoye Y Olukotun, Backer Marianne De, Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Mauro Ferrari, Michael S Perry, Patrick O'brien and William D Waddill.
View institutional ownership trends.

Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARWR stock can currently be purchased for approximately $30.93.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a market capitalization of $3.27 billion and generates $138.29 million in revenue each year. The biotechnology company earns $-140,850,000.00 in net income (profit) each year or ($1.48) on an earnings per share basis.

The company employs 329 workers across the globe.

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The official website for the company is www.arrowheadpharma.com. The biotechnology company can be reached via phone at (626) 304-3400, via email at ir@arrowheadpharma.com, or via fax at 626-304-3401.